Golden State Wealth Management LLC Takes $857,000 Position in Pfizer Inc. (NYSE:PFE)

Golden State Wealth Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 32,320 shares of the biopharmaceutical company’s stock, valued at approximately $857,000.

Several other hedge funds also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP raised its holdings in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the third quarter worth $35,000. Joseph Group Capital Management increased its position in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the period. Finally, Sugar Maple Asset Management LLC purchased a new position in Pfizer in the 4th quarter worth $43,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research reports. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Down 2.3 %

Shares of PFE stock opened at $25.83 on Friday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $146.35 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 0.66 and a beta of 0.64. The company’s 50-day moving average price is $26.29 and its 200-day moving average price is $27.78. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 EPS. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.66%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is currently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.